375 related articles for article (PubMed ID: 27848178)
1. Dysregulation of TET2 in hematologic malignancies.
Chiba S
Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
[TBL] [Abstract][Full Text] [Related]
2. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
3. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
4. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.
Joshi K; Zhang L; Breslin S J P; Kini AR; Zhang J
J Exp Clin Cancer Res; 2022 Oct; 41(1):294. PubMed ID: 36203205
[TBL] [Abstract][Full Text] [Related]
5. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Nakajima H; Kunimoto H
Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
[TBL] [Abstract][Full Text] [Related]
6. Ten-Eleven-Translocation Genes in Cancer.
Wang Y; Wang X; Lu J
Cancer Treat Res; 2023; 190():363-373. PubMed ID: 38113007
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies.
Li W; Xu L
Oncol Res Treat; 2019; 42(6):309-318. PubMed ID: 31055566
[TBL] [Abstract][Full Text] [Related]
8. TET2 in Normal and Malignant Hematopoiesis.
Bowman RL; Levine RL
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28242787
[TBL] [Abstract][Full Text] [Related]
9. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
10. TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells.
Secardin L; Limia CEG; di Stefano A; Bonamino MH; Saliba J; Kataoka K; Rehen SK; Raslova H; Marty C; Ogawa S; Vainchenker W; Monte-Mor BDCR; Plo I
Stem Cell Res; 2020 Apr; 44():101755. PubMed ID: 32193150
[TBL] [Abstract][Full Text] [Related]
11. The TET2 interactors and their links to hematological malignancies.
Pan F; Weeks O; Yang FC; Xu M
IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
[TBL] [Abstract][Full Text] [Related]
12. Tet2 at the interface between cancer and immunity.
Jiang S
Commun Biol; 2020 Nov; 3(1):667. PubMed ID: 33184433
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of ten-eleven translocation genes in endometrial cancers.
Ciesielski P; Jóźwiak P; Wójcik-Krowiranda K; Forma E; Cwonda Ł; Szczepaniec S; Bieńkiewicz A; Bryś M; Krześlak A
Tumour Biol; 2017 Mar; 39(3):1010428317695017. PubMed ID: 28349832
[TBL] [Abstract][Full Text] [Related]
14. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
15. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
Li R; Xu MJ; Yang FC; Zhou Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
[TBL] [Abstract][Full Text] [Related]
16. TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma.
Murata A; Baba Y; Ishimoto T; Miyake K; Kosumi K; Harada K; Kurashige J; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Yamamoto M; Oda S; Watanabe M; Nakao M; Baba H
Oncotarget; 2015 Sep; 6(27):23372-82. PubMed ID: 26093090
[TBL] [Abstract][Full Text] [Related]
17. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
[TBL] [Abstract][Full Text] [Related]
18. TET2 mutation as prototypic clonal hematopoiesis lesion.
Guarnera L; Jha BK
Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
[TBL] [Abstract][Full Text] [Related]
19. [Significance of TET2 mutations in myeloid and lymphoid neoplasms].
Chiba S
Rinsho Ketsueki; 2016 Jun; 57(6):715-22. PubMed ID: 27384850
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
